Navigation Links
Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million
Date:8/6/2008

continues to exceed our output expectations. Most importantly, New Bedford allows us to leverage increased capacity at an opportunistic time, while deepening an important customer relationship and broadening our customer reach in the region.

Mr. Moore continued, "We continue to place a major emphasis on improving the operational and financial performance of our Sheffield, UK facility. Following a focus on meeting current and past due customer demand in the first quarter, our Sheffield team is implementing all of the strategic initiatives, processes and controls designed to improve its performance. We will continue executing this multi-faceted plan over the second half of 2008. We remain confident that our Sheffield facility will see improved performance in the third quarter and will remain on track to reach profitability in the fourth quarter of 2008."

Financial Guidance

The following forward-looking estimates regarding 2008 earnings guidance are based on current market conditions and foreign currency comparisons. Actual results may differ materially, and we refer you to forward-looking statements located at the end of the press release.

For the full year 2008, the Company is increasing revenue guidance to a range of $410 million to $420 million, up from the previously announced range of $395 million to $405 million. This increase is based on current order flow and anticipated customer demand for the remainder of 2008.

For the full year 2008, the Company is reaffirming guidance for diluted earnings per share in the range of $0.75 to $0.77. This guidance includes an increased effective tax rate for 2008. Regarding the Sheffield operating unit, the Company expects to incur a smaller net loss during the third quarter 2008 prior to the unit reaching profitability in the fourth quarter of 2008.

Conference Call

Symmetry Medical will host a conference all at 8:00 a.m. ET on August 6, 2008. A live Web cast of the conference
'/>"/>

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Symmetry Medical to Report Second Quarter 2008 Financial Results on August 6, 2008
2. Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million
3. Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008
4. Symmetry Medical Reports Full Year 2007 Financial Results
5. Symmetry Medical Delays 10-K Filing to Complete Review
6. Symmetry Medical to Expand Malaysian Operations
7. Facial asymmetry persists despite surgery to correct congenital deformity
8. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
9. Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility
10. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
11. Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 1Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 2Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 1CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 2CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 4CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 5A Little Cash Buys a Lot of Calories at the Corner Store 59282 1A Little Cash Buys a Lot of Calories at the Corner Store 59282 2